Literature DB >> 21057959

Effect of 4-aminopyridine on gravity dependence and neural integrator function in patients with idiopathic downbeat nystagmus.

T Sander1, A Sprenger, S Marti, T Naumann, D Straumann, C Helmchen.   

Abstract

Downbeat nystagmus (DBN) is a frequent sign in patients with cerebellar degeneration. It consists of an upward drift of the eye that does not depend on vertical head position (spontaneous drift, SD), a gravity-dependent component (GD), and a gaze-evoked drift reflecting gaze-holding impairment (deficient neural integrator function). The potassium-channel blocker 4-aminopyridine (4-AP) is reported to reduce DBN in patients with cerebellar atrophy but with little or no effect in patients with idiopathic DBN. We prospectively studied the effect of 4-AP on all three components in a large (n = 24) group of the clinically frequent idiopathic DBN. DBN was reduced by 22-31% when the head was off the head erect position. In contrast, there was no effect on vertical gaze-evoked drift. This indicates the therapeutic efficacy of 4-AP not only in patients with cerebellar atrophy but also in idiopathic DBN patients. This beneficial effect, which might be missed when gravity-dependent head positions are not tested, was not related to an improvement of gaze-holding deficit. We suggest it may be related to the restored inhibition of the overacting otolith-ocular reflex.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21057959     DOI: 10.1007/s00415-010-5806-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

1.  4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain.

Authors:  R Kalla; S Glasauer; F Schautzer; N Lehnen; U Büttner; M Strupp; T Brandt
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

2.  Downbeat nystagmus: aetiology and comorbidity in 117 patients.

Authors:  J N Wagner; M Glaser; T Brandt; M Strupp
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09-14       Impact factor: 10.154

3.  Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.

Authors:  A Sprenger; H Rambold; T Sander; S Marti; K Weber; D Straumann; C Helmchen
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

4.  Gravity dependence of ocular drift in patients with cerebellar downbeat nystagmus.

Authors:  Sarah Marti; Antonella Palla; Dominik Straumann
Journal:  Ann Neurol       Date:  2002-12       Impact factor: 10.422

5.  Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.

Authors:  M Strupp; O Schüler; S Krafczyk; K Jahn; F Schautzer; U Büttner; T Brandt
Journal:  Neurology       Date:  2003-07-22       Impact factor: 9.910

6.  4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.

Authors:  Roger Kalla; Stefan Glasauer; Ulrich Büttner; Thomas Brandt; Michael Strupp
Journal:  Brain       Date:  2007-07-29       Impact factor: 13.501

7.  The intensity of downbeat nystagmus during daytime.

Authors:  Rainer Spiegel; Nicole Rettinger; Roger Kalla; Nadine Lehnen; Dominik Straumann; Thomas Brandt; Stefan Glasauer; Michael Strupp
Journal:  Ann N Y Acad Sci       Date:  2009-05       Impact factor: 5.691

8.  A model-based theory on the origin of downbeat nystagmus.

Authors:  Sarah Marti; Dominik Straumann; Ulrich Büttner; Stefan Glasauer
Journal:  Exp Brain Res       Date:  2008-05-08       Impact factor: 1.972

9.  Aminopyridines for the treatment of cerebellar and ocular motor disorders.

Authors:  Michael Strupp; Roger Kalla; Stefan Glasauer; Judith Wagner; Katharina Hüfner; Klaus Jahn; Thomas Brandt
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

10.  Three-dimensional eye position and slow phase velocity in humans with downbeat nystagmus.

Authors:  S Glasauer; M Hoshi; U Kempermann; T Eggert; U Büttner
Journal:  J Neurophysiol       Date:  2003-01       Impact factor: 2.714

  10 in total
  9 in total

Review 1.  Recent advances in the diagnosis and treatment of balance disorders.

Authors:  Klaus Jahn; Marianne Dieterich
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

Review 2.  What we know about the generation of nystagmus and other ocular oscillations: are we closer to identifying therapeutic targets?

Authors:  Rebecca Jane McLean; Irene Gottlob; Frank Antony Proudlock
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

3.  Inverse eye position dependency of downbeat nystagmus in midline medullary lesion.

Authors:  Christoph Helmchen; Stefan Glasauer; Andreas Sprenger
Journal:  J Neurol       Date:  2013-10-20       Impact factor: 4.849

Review 4.  Progress in neuro-otology research in the last year.

Authors:  Alexander A Tarnutzer; Dominik Straumann
Journal:  J Neurol       Date:  2012-09-15       Impact factor: 4.849

5.  The ataxic mouse as a model for studying downbeat nystagmus.

Authors:  John S Stahl; Zachary C Thumser; Brian S Oommen
Journal:  J Vestib Res       Date:  2012       Impact factor: 2.435

6.  Postural Ataxia in Cerebellar Downbeat Nystagmus: Its Relation to Visual, Proprioceptive and Vestibular Signals and Cerebellar Atrophy.

Authors:  Christoph Helmchen; Jan-Birger Kirchhoff; Martin Göttlich; Andreas Sprenger
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

7.  Postural Control in Bilateral Vestibular Failure: Its Relation to Visual, Proprioceptive, Vestibular, and Cognitive Input.

Authors:  Andreas Sprenger; Jann F Wojak; Nico M Jandl; Christoph Helmchen
Journal:  Front Neurol       Date:  2017-09-01       Impact factor: 4.003

8.  Clinical and electrophysiological results of eye muscle surgery in 17 patients with downbeat nystagmus.

Authors:  Richard W Hertle; Ashraf Ahmad
Journal:  Indian J Ophthalmol       Date:  2019-01       Impact factor: 1.848

9.  4-aminopyridine does not enhance flocculus function in tottering, a mouse model of vestibulocerebellar dysfunction and ataxia.

Authors:  John S Stahl; Zachary C Thumser
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.